A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults who are Hospitalized with Influenza Caused by Type A Strains (protocol D6000C00003)
|Effective start/end date||7/1/16 → 12/31/17|
- MedImmune, LLC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.